FDA Grants Priority Review to Takeda's Zasocitinib for Plaque Psoriasis Treatment

The U.S. FDA has accepted Takeda's New Drug Application for zasocitinib (TAK-279) for priority review, targeting moderate-to-severe plaque psoriasis in adults. This decision is based on strong Phase 3 clinical trial data showing rapid and consistent skin clearance. A PDUFA target action date is set for the first quarter of 2027, indicating a potential new treatment option for patients.